The Authors Reply

The Authors Reply e22 LETTER TO THE EDITOR choice. It provides important information on functional outcome, information we can use to counsel patients about the quality of life of the different treatment options. To the Editor—Thank you for the comments. As the We acknowledge the “far more interesting question” authors point out, our comparison carries some apple- on a different group of patients with low-risk tumors (safe orange effect, because it is not a randomized trial. Our circumferential resection margin, ≤cN1, ≤cT3a/b), who watch-and-wait patients all had the standard indication could be treated only by surgery, but who also have a higher for neoadjuvant chemoradiation. This is why we chose chance of organ preservation when treated with upfront a control group consisting of patients with neoadjuvant chemoradiation. These treatment choices for this group of chemoradiation and total mesorectal excision resection. patients are investigated in the recently started STARTREC This would have been the treatment if they had followed the randomized trial (clinicaltrials.gov: NCT02945566). standard guidelines. An additional assumption underlying the choice of our control group is that the functional Britt J.P. Hupkens, M.D. problems are mainly caused by the chemoradiation and/ Geerard L. Beets, M.D., Ph.D. or the total mesorectal excision resection, and not by the Stéphanie O. Breukink, M.D., Ph.D. degree of response. That is why we still feel this is a valid Maastricht, The Netherlands © The ASCRS 2018 Dis Colon Rectum 2018; 61: e22 DOI: 10.1097/DCR.0000000000001019 © The ASCRS 2018 Copyright © The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diseases of the Colon & Rectum Wolters Kluwer Health

Loading next page...
1 Page
 
/lp/wolters_kluwer/the-authors-reply-CwPQD4CCku
Publisher
Wolters Kluwer Health
Copyright
© The ASCRS 2018
ISSN
0012-3706
eISSN
1530-0358
D.O.I.
10.1097/DCR.0000000000001019
Publisher site
See Article on Publisher Site

Abstract

e22 LETTER TO THE EDITOR choice. It provides important information on functional outcome, information we can use to counsel patients about the quality of life of the different treatment options. To the Editor—Thank you for the comments. As the We acknowledge the “far more interesting question” authors point out, our comparison carries some apple- on a different group of patients with low-risk tumors (safe orange effect, because it is not a randomized trial. Our circumferential resection margin, ≤cN1, ≤cT3a/b), who watch-and-wait patients all had the standard indication could be treated only by surgery, but who also have a higher for neoadjuvant chemoradiation. This is why we chose chance of organ preservation when treated with upfront a control group consisting of patients with neoadjuvant chemoradiation. These treatment choices for this group of chemoradiation and total mesorectal excision resection. patients are investigated in the recently started STARTREC This would have been the treatment if they had followed the randomized trial (clinicaltrials.gov: NCT02945566). standard guidelines. An additional assumption underlying the choice of our control group is that the functional Britt J.P. Hupkens, M.D. problems are mainly caused by the chemoradiation and/ Geerard L. Beets, M.D., Ph.D. or the total mesorectal excision resection, and not by the Stéphanie O. Breukink, M.D., Ph.D. degree of response. That is why we still feel this is a valid Maastricht, The Netherlands © The ASCRS 2018 Dis Colon Rectum 2018; 61: e22 DOI: 10.1097/DCR.0000000000001019 © The ASCRS 2018 Copyright © The American Society of Colon & Rectal Surgeons, Inc. Unauthorized reproduction of this article is prohibited.

Journal

Diseases of the Colon & RectumWolters Kluwer Health

Published: Mar 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off